Pierre S C, Schmidt R, Brenneis C, Michaelis M, Geisslinger G, Scholich K
Pharmazentrum frankfurt, ZAFES, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.
Br J Pharmacol. 2007 Jun;151(4):494-503. doi: 10.1038/sj.bjp.0707239. Epub 2007 Apr 16.
Dipyrone is a potent analgesic drug that has been demonstrated to inhibit cyclooxygenase (COX). In contrast to classical COX-inhibitors, such as aspirin-like drugs, dipyrone has no anti-inflammatory effect and a low gastrointestinal toxicity, indicating a different mode of action. Here, we aimed to investigate the effects of dipyrone on COX.
The four major metabolites of dipyrone, including the two pharmacologically active metabolites, 4-methyl-amino-antipyrine (MAA) and amino-antipyrine (AA), were used to characterise their binding to COX and haem as well as their effects on the biochemical properties of COX. Mass spectrometry, UV and visible photometry were used to study binding and prostaglandin production. Levels of anti-oxidant enzymes were assessed by Western blotting.
The pharmacologically active metabolites of dipyrone, MAA and AA, did not inhibit COX activity in vitro like classical COX inhibitors, but instead redirected the prostaglandin synthesis, ruling out inhibition of COX through binding to its active site. We found that MAA and AA formed stable complexes with haem and reacted with hydrogen peroxide in presence of haem, ferrous ions (Fe(2+)) or COX. Moreover, MAA reduced Fe(3+) to Fe(2+) and accordingly increased lipid peroxidation and the expression of anti-oxidant enzymes in cultured cells and in vivo.
Our data suggest that the pharmacologically active metabolites of dipyrone inhibit COX activity by sequestering radicals which initiate the catalytic activity of this enzyme or through the reduction of the oxidative states of the COX protein.
安乃近是一种强效镇痛药,已被证明可抑制环氧化酶(COX)。与阿司匹林类等经典COX抑制剂不同,安乃近没有抗炎作用且胃肠道毒性低,这表明其作用方式不同。在此,我们旨在研究安乃近对COX的影响。
使用安乃近的四种主要代谢产物,包括两种具有药理活性的代谢产物,4-甲基氨基安替比林(MAA)和氨基安替比林(AA),来表征它们与COX和血红素的结合以及它们对COX生化特性的影响。采用质谱、紫外和可见分光光度法研究结合情况和前列腺素生成。通过蛋白质印迹法评估抗氧化酶水平。
安乃近的药理活性代谢产物MAA和AA在体外不像经典COX抑制剂那样抑制COX活性,而是改变了前列腺素的合成,排除了通过与COX活性位点结合来抑制COX的可能性。我们发现MAA和AA与血红素形成稳定复合物,并在血红素、亚铁离子(Fe(2+))或COX存在的情况下与过氧化氢反应。此外,MAA将Fe(3+)还原为Fe(2+),从而增加了培养细胞和体内的脂质过氧化以及抗氧化酶的表达。
我们的数据表明,安乃近的药理活性代谢产物通过螯合引发该酶催化活性的自由基或通过降低COX蛋白的氧化状态来抑制COX活性。